The Science of MDHAQ/RAPID3 Scores

Dr. Pincus is clinical professor of medicine in the division of rheumatology at New York University School of Medicine and NYU Hospital for Joint Diseases in New York City. Contact him at [email protected].

References

1. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137-145.
2. Meenan RF, Gertman PM, Mason JH. Measuring health status in arthritis: The arthritis impact measurement scales. Arthritis Rheum. 1980;23:146-152.
3. Pincus T, Schur PH, Rose JA, Decker JL, Talal N. Measurement of serum DNA-binding activity in systemic lupus erythematosus. N Engl J Med. 1969;281:701-705.
4. Smith T. Questions on clinical trials (editorial). Br Med J. 1983;287:569.
5. Pincus T, Summey JA, Soraci SA, Jr., Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford health assessment questionnaire. Arthritis Rheum. 1983;26:1346-1353.
6. Pincus T, Maclean R, Yazici Y, Harrington JT. Quantitative measurement of patient status in the regular care of patients with rheumatic diseases over 25 years as a continuous quality improvement activity, rather than traditional research. Clin Exp Rheumatol. 2007;25(6 Suppl 47):S69-S81.
7. Pincus T, Swearingen C, Wolfe F. Toward a multidimensional health assessment questionnaire (MDHAQ): Assessment of advanced activities of daily living and psychological status in the patient friendly health assessment questionnaire format. Arthritis Rheum. 1999;42:2220-2230.
8. Pincus T, Sokka T, Kautiainen H. Further development of a physical function scale on a multidimensional health assessment questionnaire for standard care of patients with rheumatic diseases. J Rheumatol. 2005;32:1432-1439.
9. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum. 1984;27:864-872.
10. Kelley WN, Harris ED, Jr., Ruddy S, Sledge CB. Textbook of Rheumatology. 2nd ed. Philadelphia: W.B. Saunders; 1985.
11. Pincus T, Esther R, DeWalt DA, Callahan LF. Social conditions and self-management are more powerful determinants of health than access to care. Ann Intern Med. 1998;129:406-411.
12. Pincus T, Bergman M, Sokka T, Roth J, Swearingen C, Yazici Y. Visual analog scales in formats other than a 10 centimeter horizontal line to assess pain and other clinical data. J Rheumatol. 2008;35:1550-1558.
13. Pincus T, Bergman MJ, Yazici Y, Hines P, Raghupathi K, Maclean R. An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: Similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures. Rheumatology (Oxford). 2008;47:345-349.
14. Pincus T, Swearingen CJ, Bergman M, Yazici Y. RAPID3 (routine assessment of patient index data 3), a rheumatoid arthritis index without formal joint counts for routine care: Proposed severity categories compared to DAS and CDAI categories. J Rheumatol. 2008;35:2136-2147.
15. Stucki G, Liang MH, Stucki S, Brühlmann P, Michel BA. A self-administered rheumatoid arthritis disease activity index (RADAI) for epidemiologic research. Arthritis Rheum. 1995;38:795-798.
16. DeWalt DA, Reed GW, Pincus T. Further clues to recognition of patients with fibromyalgia from a simple 2-page patient multidimensional health assessment questionnaire (MDHAQ). Clin Exp Rheumatol. 2004;22:453-461.
17. Pincus T, Mandelin AM, Swearingen CJ. Flowsheets that include MDHAQ physical function, pain, global, and RAPID3 scores, laboratory tests, and medications to monitor patients with all rheumatic diseases: An electronic database for an electronic medical record. Rheum Dis Clin North Am. 2009;35:829-842.
18. Pincus T, Amara I, Segurado OG, Bergman M, Koch GG. Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials. J Rheumatol. 2008;35:201-205.
19. Tugwell P, Wells G, Strand V, et al. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: Sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Arthritis Rheum. 2000;43:506-514.
20. Wells G, Li T, Maxwell L, Maclean R, Tugwell P. Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. Ann Rheum Dis. 2008;67:260-265.
21. Pincus T, Swearingen CJ, Bergman MJ, et al. RAPID3 on an MDHAQ is correlated significantly with activity levels of DAS28 and CDAI, but scored in 5 versus more than 90 seconds. Arthritis Care Res. 2010;62:181-189.
22. Sackett DL, Rosenberg WM, Gray JM, Haynes RB, Richardson WS. Evidence based medicine: What it is and what it isn’t. It’s about integrating individual clinical expertise and the best external evidence. Br Med J. 1996;312:71-72.
23. Preventive Services Task Force. Guide to clinical preventive services: Report of the U.S. Preventive Services Task Force. 2nd ed. Baltimore: Williams & Wilkins; 1996.
24. Feinstein AR. An additional basic science for clinical medicine: II. The limitations of randomized trials. Ann Intern Med. 1983;99:544-550.
25. Pincus T. Rheumatoid arthritis: Disappointing long-term outcomes despite successful short-term clinical trials. J Clin Epidemiol. 1988;41:1037-1041.
26. Pincus T. Limitations of randomized controlled clinical trials to recognize possible advantages of combination therapies in rheumatic diseases. Semin Arthritis Rheum. 1993;23(Suppl 1):2-10.
27. Pincus T, Stein CM. Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: Some explanations and suggestions for future studies. Clin Exp Rheumatol. 1997;15(Suppl.17):S27-S38.
28. Pincus T, Yazici Y, Bergman MJ. Quantitative clinical rheumatology: Why is a test for anti-CCP antibodies included in most routine care for rheumatoid arthritis while a HAQ/MDHAQ remains largely a research tool? J Rheumatol. 2009;36:1563-1564.
29. Thomas JW, Zenowich E, Beckwith M, Nell LJ. Genetic origin of human anti-insulin antibodies. Human Immunol. 1989;26:333-343.
30. Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol. 1989;16:585-591.
31. Wolfe F, Hawley DJ. Remission in rheumatoid arthritis. J Rheumatol. 1985;12:245-252.
32. Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med. 1988;109:359-363.
33. Pincus T, Sokka T, Kautiainen H. Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. Arthritis Rheum. 2005; 52:1009-1019.
34. Pincus T, Furer V, Sokka T. Underestimation of the efficacy, effectiveness, tolerability, and safety of weekly low-dose methotrexate in information presented to physicians and patients. Clin Exp Rheumatol. 2010; 28(5 Suppl 61):S68-S79.
35. Sokka T, Pincus T. Poor physical function, pain and limited exercise: Risk factors for premature mortality in the range of smoking or hypertension, identified on a simple patient self-report questionnaire for usual care. BMJ Open. 2011; Published: 18 June 2011 doi:10.1136/bmjopen-2011-000070.
36. Stein CM, Pincus T. Placebo-controlled studies in rheumatoid arthritis: Ethical issues. Lancet. 1999; 353:400-403.